IPP Bureau
Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
By IPP Bureau - May 21, 2024
Additional data from APPRAISE ATP trial reinforce modular therapy approach
IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital
By IPP Bureau - May 20, 2024
The collaboration aims to bolster healthcare entrepreneurship
LVPEI raises awareness and funds for retinoblastoma treatment with WHITATHON Run
By IPP Bureau - May 20, 2024
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19
By IPP Bureau - May 20, 2024
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
By IPP Bureau - May 20, 2024
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
MMV and GSK win Society of Chemical Industry Innovation Award
By IPP Bureau - May 20, 2024
The award recognizes powerful science–industry collaborations for social good
Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution
By IPP Bureau - May 18, 2024
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib
By IPP Bureau - May 18, 2024
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Glenmark launches next phase of ‘India First Heart First’ campaign
By IPP Bureau - May 17, 2024
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Takeda appoints Annapurna Das as the General Manager, India Operations
By IPP Bureau - May 17, 2024
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
By IPP Bureau - May 17, 2024
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause
By IPP Bureau - May 17, 2024
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
By IPP Bureau - May 17, 2024
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Cipla invests additional Rs. 26 crore in Achira
By IPP Bureau - May 16, 2024
Achira is engaged in development and commercialization of PoC medical test kits in India
